Weekly Recap | Bioventus +1.66%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Bioventus (BVS) rose 1.66% to $14.07, outperforming the S&P 500, which added 0.09%, by about 1.57 percentage points. The stock opened weaker at $13.44 on Monday, recovered through midweek, and touched $14.50 on Thursday before easing back to $14.07 on Friday. Volume ran about 5% below the daily median in a week without a major catalyst.
The Week
Bioventus (BVS) rose 1.66% to $14.07, outperforming the S&P 500, which added 0.09%, by about 1.57 percentage points. The stock opened weaker at $13.44 on Monday, recovered through midweek, and touched $14.50 on Thursday before easing back to $14.07 on Friday. Volume ran about 5% below the daily median in a week without a major catalyst.
Analyst Ratings
All five covering analysts rate BVS as either buy (3) or overweight (2), with no hold, underweight, or sell ratings. The consensus recommendation is strong buy, and the consensus target of $17.60 sits about 25.1% above the current price. Targets range from $15.00 to $19.00, and BVS ranks 19th out of 35 medical supplies companies.
The Week Ahead
No company-specific reports or events are scheduled. Macro data due next week include the NFIB Small Business Optimism Index on 8 September, followed by initial jobless claims, final demand PPI, and existing home sales on 10 September. These releases could shape risk appetite for small- and mid-cap medical names like BVS.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.